Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.
Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulié C, Wirden M, Katlama C, Yeni P, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D. Larrouy L, et al. Among authors: visseaux b. Antimicrob Agents Chemother. 2011 Apr;55(4):1754-7. doi: 10.1128/AAC.01049-10. Epub 2011 Jan 31. Antimicrob Agents Chemother. 2011. PMID: 21282435 Free PMC article.
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Visseaux B, et al. Antimicrob Agents Chemother. 2012 Jan;56(1):137-9. doi: 10.1128/AAC.05313-11. Epub 2011 Nov 7. Antimicrob Agents Chemother. 2012. PMID: 22064539 Free PMC article.
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D. Charpentier C, et al. Among authors: visseaux b. J Antimicrob Chemother. 2012 Jun;67(6):1459-61. doi: 10.1093/jac/dks067. Epub 2012 Mar 1. J Antimicrob Chemother. 2012. PMID: 22382470
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group. Charpentier C, et al. Among authors: visseaux b. J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14. J Antimicrob Chemother. 2013. PMID: 23152480 Clinical Trial.
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS139 TRIO Trial study group. Charpentier C, et al. Among authors: visseaux b. PLoS One. 2013;8(1):e53621. doi: 10.1371/journal.pone.0053621. Epub 2013 Jan 17. PLoS One. 2013. PMID: 23349724 Free PMC article. Clinical Trial.
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG. Lambert-Niclot S, et al. Among authors: visseaux b. J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29. J Antimicrob Chemother. 2013. PMID: 23361642
174 results